MURRIETA, CA--(MARKET WIRE)--Sep 29, 2008 -- CLX Medical, Inc. (OTC BB:CLXN.OB - News), which is focused on the marketing and distribution of unique medical diagnostic testing products, today issued the September 2008 edition of the company's investor newsletter, which reviews the recent definitive agreement to acquire ThyroTest®, a rapid thyroid stimulating hormone (TSH) screening device used for the detection of hypothyroidism in adults, a common thyroid disease.

A PDF version of the September 2008 newsletter can be viewed on the company's corporate website at http://www.clxmedical.com/newsletters.php.

CLX Medical has entered into a definitive agreement to acquire ThyroTest® and is seeking to close the acquisition as soon as possible. The newsletter includes articles on both the definitive agreement and the Current Report on Form 8-K filed with the Securities and Exchange Commission detailing the agreement.

The newsletter also highlights the recent Form 4 filings made by the company's Board of Directors when they acquired additional shares of CLX common stock. Directors Robert McCoy, Patrick Edgerton and James Bickel each filed a Form 4 Statement of Change in Beneficial Ownership of Securities with the S.E.C. on September 12, 2008. The stock acquired by each of the Directors was granted by the company dating back as far as January 2007 as part of their respective compensation packages.

Another newsletter article reviews the three-year employment agreement that CLX Medical has entered into with Chief Executive Officer Vera Leonard. Ms. Leonard's compensation package includes a combination of a base salary, a schedule of salary increases based on a variety of factors including the company's revenue and profit performance, the granting of restricted common stock, medical coverage, and expense reimbursements.

Ms. Leonard's CEO Greeting in the newsletter is taken from her recent discussion of the opportunities presented by the acquisition of ThyroTest®, including the projected worldwide screening market for the product. ThyroTest® is FDA cleared and has also achieved CLIA waived status, so the test can be administered in the more than 100,000 CLIA waived doctors' offices in the U.S., as well as in any non-waived laboratory. ThyroTest® is a qualitative rapid diagnostic test that allows physicians to screen adult patients for hypothyroidism in approximately ten minutes with a whole blood sample.

To sign up to receive information by email directly from CLX Medical, Inc. when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php.

About CLX Medical, Inc.

CLX Medical, Inc. (www.clxmedical.com) holds a 51% equity interest in Zonda, Inc. (www.zondaincusa.com), which has developed several rapid point of care tests for medical and non-medical markets, including a rapid test for chlamydia. CLX has also entered into a definitive agreement to acquire ThyroTest®, a rapid thyroid stimulating hormone (TSH) screening device used for the detection of hypothyroidism in adults, a common thyroid disease. CLX Medical is focused on the successful worldwide distribution of these and any additional products it may acquire or license.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Medical, Inc. are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Medical's control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

     Contact:
     Gemini Financial Communications, Inc.
     A. Beyer
     951-677-8073
     Email Contact